You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES
  1. PLASMA & BIOTHERAPIES - 22-03-2017

    Article by Prof. Farrugia and Daniela Scaramuccia published on “Biologicals”

    International medical journal hosts review of contract plasma fractionation dynamics

    read more 
  2. PLASMA & BIOTHERAPIES - 08-11-2016

    FDA Acceptance of BLA Submission for Human Rabies Immunoglobulin

    Announcement by Kedrion Biopharma and Kamada. Regulatory decision expected in August 2017

    read more 
  3. PLASMA & BIOTHERAPIES - 16-09-2016

    Humanitarian Factor IX donation to Afghanistan

    Kedrion Biopharma confirms its commitment to broaden access to therapies in developing Countries

    read more 
  4. PLASMA & BIOTHERAPIES - 13-09-2016

    Kedrion and Kamada seek FDA approval of IgG as a post-exposure treatment

    BLA has been submitted on September 1, 2016. Companies planning for decision from FDA in mid-2017

    read more 

Pages

For more information please contact: pressoffice@kedrion.com